Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC
Sponsor: GeneCast Biotechnology Co., Ltd.
Listed as NCT04405661, this observational or N/A phase trial focuses on NSCLC and remains ongoing. Sponsored by GeneCast Biotechnology Co., Ltd., it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jul 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Jul 2022 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Recruiting
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GeneCast Biotechnology Co., Ltd.
- Guangzhou Institute of Respiratory Disease
For direct contact, visit the study record on ClinicalTrials.gov .